

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of) **MAIL STOP PCT**
Stephane Paul)
Application No.: 10/565,371) Group Art Unit:
Filing Date: January 23, 2006) Examiner:
Title: NOVEL MULTIFUNCTIONAL) Confirmation No.:
CYTOKINES)
)

**FIRST
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a FIRST Information Disclosure Statement (IDS) and accompanying form PTO-1449 for the above-identified patent application.


- No additional fee for submission of an IDS is required.
- The fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e), and the fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- Charge _____ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of _____ is enclosed for the fee due.
- Charge _____ to credit card for the fee due. Form PTO-2038 is attached.
- The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date December 13, 2006

By:


Susan M. Dadio
Registration No. 40373

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of) **MAIL STOP PCT**
Stéphane Paul)
Application No.: 10/565,371) Group Art Unit:
Filed: January 23, 2006) Examiner:
For: NOVEL MULTIFUNCTIONAL) Confirmation No.:
CYTOKINES)
)
)
)
)

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. patents are not enclosed since it is no longer required according to the July 11, 2003 waiver of the requirement for copies of cited U.S. patents and U.S. patent application publications in national patent applications filed after June 30, 2003 and international applications entering the national stage under 35 U.S.C. § 371 after June 30, 2003.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

The Examiner's attention is directed to copending application number 10/895,396, naming Stéphane Paul as inventor(s) and filed on July 21, 2004, and the documents cited therein. According to the Private Patent Application Information Retrieval System (PAIRS), the application is available in electronic format therefore not requiring a copy to be enclosed.

In accordance with MPEP § 609 III C(2) (August 2001, page 600-131), the Office is requested to return a copy of this Information Disclosure Statement with the Examiner's initials adjacent to this paragraph indicating that this copending application has been considered. By citation to the copending application,

confidentiality is not waived and the Office is requested to maintain the confidentiality of the copending application under 35 U.S.C. § 122.

This Information Disclosure Statement contains information which is not in the English language but was cited in a search report or other action by a foreign patent office in a counterpart foreign application. In accordance with MPEP § 609 III A(3), an English language version of the search report or action which indicates the degree of relevance found by the foreign office is being submitted herewith.


To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: December 13, 2006

By:


Susan M. Dadio
Registration No. 40373

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
 (use as many sheets as necessary)

Sheet 1 of 3

Application Number	10/565,371
Filing Date	January 23, 2006
First Named Inventor	Stephane Paul
Examiner Name	
Attorney Docket No.	1032751-000123

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	6,552,005	B1	BUCHSBAUM et al.	04-22-2003
	5,359,035		HABERMANN	10-25-1994

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS				Cited in Spec
					Eng Lang Summary	Partial Translation	Partial Translation	Report	
	0 158 198	A1	EP	10-16-1985				X	
	0 225 579	B1	EP	06-16-1987				X	
	0 288 809	B1	EP (Corres. To USP 5,359,035)	11-02-1988				X	
	0 816 510	A1	EP	01-07-1998				X	
	94/21792	A2	WO	09-29-1994				X	
	98/40498	A2	WO	09-17-1998				X	
	99/36440	A2	WO	07-22-1999				X	
	98/08947	A1	WO	03-05-1998				X	
	93/20849	A1	WO	10-28-1993				X	
	99/60128	A1	WO	11-25-1999				X	
	02/102404	A1	WO	12-27-2002				X	
	01/93898	A1	WO	12-13-2001				X	
	03/035105	A2	WO	05-01-2003				X	
	01/68896	A1	WO	09-20-2001				X	
	01/10912	A1	WO	02-15-2001				X	
	02/101049	A2	WO	12-19-2002				X	

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	International Search Report issued in corres. PCT/EP2004/008114, March 31, 2005, EPO, Rijswijk, NL
	ROCK, F. et al., "Overexpression and structure – function analysis of a bioengineered IL-2/IL-6 chimeric lymphokine", Protein Engineering, September 1992, pp. 583-591, vol. 5, no. 6, Oxford University Press, Surrey, GB
	KAUFMANN, A.M., et al., "Comparison of Cytokines and CD80 for Enhancement of Immunogenicity of Cervical Cancer Cells", Immunobiology, October 2000, pp. 339-352, vol. 202, no. 4, Urban & Fischer Verlag, GERMANY
	KONDO, M., et al., "Enhancement of Interleukin-2-Induced Lymphokine-Activated Killer Activity by Interleukin 7 against Autologous Human Renal Cell Carcinoma", Oncology, November 1998, pp. 588-593, vol. 55, no. 6, S. Karger AG, Basel, SWITZERLAND

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
 (use as many sheets as necessary)

Sheet 2 of 3

Application Number	10/565,371
Filing Date	January 23, 2006
First Named Inventor	Stephane Paul
Examiner Name	
Attorney Docket No.	1032751-000123

JU, Dian Wen, et al., "Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity", Journal of Cancer Research and Clinical Oncology, 1998, pp. 683-689, vol. 124, no. 12, Springer-Verlag, Heidelberg, GERMANY
SHANAFELT, Armen B., et al., "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo", Nature Biotechnology, November 2000, pp. 1197-1202, vol. 18, no. 11, Nature America Inc. - http://biotech.nature.com , USA
WIGGINTON, Jon M., et al., "Synergistic Engagement of an Ineffective Endogenous Anti-Tumor Immune Response and Induction of IFN- γ and FAS-Ligand-Dependent Tumor Eradication by Combined Administration of IL-18 and IL-2", The Journal of Immunology, October 15, 2002, pp. 4467-4474, vol. 169, no. 8, The American Association of Immunologists, Inc., Baltimore, MD
SON, Young-Ik, et al., "Interleukin-18 (IL-18) Synergizes with IL-2 to Enhance Cytotoxicity, Interferon- γ Production, and Expansion of Natural Killer Cells", Cancer Research, February 1, 2001, pp. 884-888, vol. 61, no. 3, American Association for Cancer Research, Baltimore, MD
WANG, Q., et al., "Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma", Gene Therapy, April 2001, pp. 542-550, vol. 8, no. 7, Nature Publishing Group, London, ENGLAND
SLOS, Philippe, et al., "Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: Induction of CD8 $^{+}$ T-cell immunity and NK activity", Cancer Gene Therapy, 2001, pp. 321-332, Vol. 8, No. 5, Nature Publishing Group, London, ENGLAND
CAO, Renhai, et al., "Interleukin-18 acts as an angiogenesis and tumor suppressor", The FASEB Journal, December 1999, pp. 2195-2202, Vol. 13, Federation of American Societies for Experimental Biology, Bethesda, MD
MILLER, Patrice W., et al., "Intratumoral Administration of Adenoviral Interleukin 7 Gene-Modified Dendritic Cells Augments Specific Antitumor Immunity and Achieves Tumor Eradication", Human Gene Therapy, January 2000, pp. 53-65, vol. 11, Mary Ann Liebert, Inc., New York, NEW YORK
NAKANISHI, Kenji, et al., "Interleukin-18 Regulates Both TH1 and TH2 Responses", Annu. Rev. Immunol., 2001, pp. 423-474, vol. 19, Annual Reviews, Palo Alto, CA
MICALLEF, Mark J., et al., "In vivo antitumor effects of murine interferon- γ -inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites", Cancer Immunol Immunother, 1997, pp. 361-367, vol. 43, Springer-Verlag, Heidelberg, GERMANY
OSAKI, Tadashi, et al., "IFN- γ -Inducing Factor/IL-18 Administration Mediates IFN- γ - and IL-12-Independent Antitumor Effects", The Journal of Immunology, 1998, pp. 1742-1749, vol. 160, The American Association of Immunologists, Baltimore, MARYLAND
OSAKI, T., et al., "Potent antitumor effects mediated by local expression of the mature form of the interferon- γ inducing factor, interleukin-18 (IL-18)", Gene Therapy, 1999, pp. 808-815, vol. 6, Stockton Press, United Kingdom
HASHIMOTO, Wataru, et al., "Differential Antitumor Effects of Administration of Recombinant IL-18 or Recombinant IL-12 are Mediated Primarily by Fas-Fas Ligand- and Perforin-Induced Tumor Apoptosis, Respectively", The Journal of Immunology, 1999, pp. 583-589, vol. 163, The American Association of Immunologists, Baltimore, MARYLAND
KIM, Soo-Hyun, et al., "Identification of Amino Acid Residues Critical for Biological Activity in Human Interleukin-18", The Journal of Biological Chemistry, March 29, 2002, pp. 10998-11003, Vol. 277, No. 13, The American Society for Biochemistry and Molecular Biology, Inc., Baltimore, MARYLAND
KIM, Soo-Hyun M., et al., "Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein", Proc. Natl. Acad. Sci., March 13, 2001, pp. 3304-3309, vol. 98, no. 6, USA
DANTHINNE, X., et al., "Production of first generation adenovirus vectors: a review", Gene Therapy, 2000, pp. 1707-1714, vol. 7, Macmillan Publishers Ltd., USA

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Application Number	10/565,371
Filing Date	January 23, 2006
First Named Inventor	Stephane Paul
Examiner Name	
Attorney Docket No.	1032751-000123

HE, Z., et al., "Viral Recombinant Vaccines to the E6 and E7 Antigens of HPV-16", Virology, 2000, pp. 146-161, Vol. 270, Academic Press, USA
KOYAMA, Fumikazu, et al., "Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of <i>Escherichia coli</i> cytosine deaminase gene and <i>Escherichia coli</i> uracil phosphoribosyltransferase gene with 5-fluorocytosine", Cancer Gene Therapy, 2000, pp. 1015-1022, Vol. 7, No. 7, Nature America, Inc., USA

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.